Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. January 2010, 50 (Suppl 1): S16–23. PMID 20067388. doi:10.1086/647939.
Rawat A, Singh P, Jyoti A, Kaushik S, Srivastava VK. Averting transmission: A pivotal target to manage amoebiasis. Chemical Biology & Drug Design. August 2020, 96 (2): 731–744. PMID 32356312. S2CID 218475533. doi:10.1111/cbdd.13699.
Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, Poston L. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG. January 2006, 113 (1): 65–74. PMID 16398774. S2CID 11366650. doi:10.1111/j.1471-0528.2005.00788.x.
Nori D, Cain JM, Hilaris BS, Jones WB, Lewis JL. Metronidazole as a radiosensitizer and high-dose radiation in advanced vulvovaginal malignancies, a pilot study. Gynecologic Oncology. August 1983, 16 (1): 117–28. PMID 6884824. doi:10.1016/0090-8258(83)90017-3.
Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. The Canadian Journal of Neurological Sciences. November 2013, 40 (6): 768–776. PMID 24257215. doi:10.1017/s0317167100015870.
Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindeløv B, Jørgensen K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology. February 1998, 46 (2): 135–46. PMID 9510041. doi:10.1016/s0167-8140(97)00220-x.
Iqbal SM, Murthy JG, Banerjee PK, Vishwanathan KA. Metronidazole ototoxicity--report of two cases. The Journal of Laryngology and Otology. April 1999, 113 (4): 355–357. PMID 10474673. S2CID 45989669. doi:10.1017/s0022215100143968.
Lawford R, Sorrell TC. Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report. Clinical Infectious Diseases. August 1994, 19 (2): 346–348. PMID 7986915. doi:10.1093/clinids/19.2.346.
Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, Vougiouklakis T, Marselos M. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. International Journal of Toxicology. 2007, 26 (5): 423–432. PMID 17963129. S2CID 41230661. doi:10.1080/10915810701583010.
Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clinic Proceedings. February 1988, 63 (2): 147–153. PMID 3339906. doi:10.1016/s0025-6196(12)64947-7.
Chaturvedi S, Malik MY, Rashid M, Singh S, Tiwari V, Gupta P, Shukla S, Singh S, Wahajuddin M. Mechanistic exploration of quercetin against metronidazole induced neurotoxicity in rats: Possible role of nitric oxide isoforms and inflammatory cytokines. Neurotoxicology. July 2020, 79: 1–10. Bibcode:2020NeuTx..79....1C. PMID 32151614. doi:10.1016/j.neuro.2020.03.002.
Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ethanol interaction. The American Journal of Forensic Medicine and Pathology. December 1996, 17 (4): 343–346. PMID 8947362. doi:10.1097/00000433-199612000-00013.
Kudo T, Endo Y, Taguchi R, Yatsu M, Ito K. Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. May 2015, 45 (5): 413–419. PMID 25470432. S2CID 26910995. doi:10.3109/00498254.2014.990948.
Tirkkonen T, Heikkilä P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. Journal of Internal Medicine. October 2010, 268 (4): 359–366. PMID 20698928. S2CID 45449460. doi:10.1111/j.1365-2796.2010.02257.x.
Alauzet C, Aujoulat F, Lozniewski A, Marchandin H. A sequence database analysis of 5-nitroimidazole reductase and related proteins to expand knowledge on enzymes responsible for metronidazole inactivation. Anaerobe. February 2019, 55: 29–34. PMID 30315962. doi:10.1016/j.anaerobe.2018.10.005.已忽略未知参数|orig-date= (帮助)
Leiros HK, Kozielski-Stuhrmann S, Kapp U, Terradot L, Leonard GA, McSweeney SM. Structural basis of 5-nitroimidazole antibiotic resistance: the crystal structure of NimA from Deinococcus radiodurans. The Journal of Biological Chemistry. December 2004, 279 (53): 55840–55849. PMID 15492014. doi:10.1074/jbc.M408044200(英语).
Suárez LJ, Arce RM, Gonçalves C, Furquim CP, Santos NC, Retamal-Valdes B, Feres M. Metronidazole may display anti-inflammatory features in periodontitis treatment: A scoping review. Mol Oral Microbiol. April 2024, 39 (4): 240–259. PMID 38613247. doi:10.1111/omi.12459.
Barr SC, Bowman DD, Heller RL. Efficacy of fenbendazole against giardiasis in dogs. American Journal of Veterinary Research. July 1994, 55 (7): 988–990. PMID 7978640. doi:10.2460/ajvr.1994.55.07.988.
World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Chaturvedi S, Malik MY, Rashid M, Singh S, Tiwari V, Gupta P, Shukla S, Singh S, Wahajuddin M. Mechanistic exploration of quercetin against metronidazole induced neurotoxicity in rats: Possible role of nitric oxide isoforms and inflammatory cytokines. Neurotoxicology. July 2020, 79: 1–10. Bibcode:2020NeuTx..79....1C. PMID 32151614. doi:10.1016/j.neuro.2020.03.002.
Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. January 2010, 50 (Suppl 1): S16–23. PMID 20067388. doi:10.1086/647939.
Huang Y, Shen C, Shen Y, Cui H. Assessing the Efficacy of Clotrimazole and Metronidazole Combined Treatment in Vaginitis: A Meta-Analysis. Altern Ther Health Med. January 2024, 30 (1): 186–191. PMID 37773671.
duBouchet L, Spence MR, Rein MF, Danzig MR, McCormack WM. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sexually Transmitted Diseases. March 1997, 24 (3): 156–160. PMID 9132982. S2CID 6617019. doi:10.1097/00007435-199703000-00006.
Rawat A, Singh P, Jyoti A, Kaushik S, Srivastava VK. Averting transmission: A pivotal target to manage amoebiasis. Chemical Biology & Drug Design. August 2020, 96 (2): 731–744. PMID 32356312. S2CID 218475533. doi:10.1111/cbdd.13699.
Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, Poston L. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG. January 2006, 113 (1): 65–74. PMID 16398774. S2CID 11366650. doi:10.1111/j.1471-0528.2005.00788.x.
Nori D, Cain JM, Hilaris BS, Jones WB, Lewis JL. Metronidazole as a radiosensitizer and high-dose radiation in advanced vulvovaginal malignancies, a pilot study. Gynecologic Oncology. August 1983, 16 (1): 117–28. PMID 6884824. doi:10.1016/0090-8258(83)90017-3.
Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. The Canadian Journal of Neurological Sciences. November 2013, 40 (6): 768–776. PMID 24257215. doi:10.1017/s0317167100015870.
Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindeløv B, Jørgensen K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology. February 1998, 46 (2): 135–46. PMID 9510041. doi:10.1016/s0167-8140(97)00220-x.
Iqbal SM, Murthy JG, Banerjee PK, Vishwanathan KA. Metronidazole ototoxicity--report of two cases. The Journal of Laryngology and Otology. April 1999, 113 (4): 355–357. PMID 10474673. S2CID 45989669. doi:10.1017/s0022215100143968.
Lawford R, Sorrell TC. Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report. Clinical Infectious Diseases. August 1994, 19 (2): 346–348. PMID 7986915. doi:10.1093/clinids/19.2.346.
Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, Vougiouklakis T, Marselos M. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. International Journal of Toxicology. 2007, 26 (5): 423–432. PMID 17963129. S2CID 41230661. doi:10.1080/10915810701583010.
Karamanakos PN. The possibility of serotonin syndrome brought about by the use of metronidazole. Minerva Anestesiologica. November 2008, 74 (11): 679. PMID 18971895.
Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clinic Proceedings. February 1988, 63 (2): 147–153. PMID 3339906. doi:10.1016/s0025-6196(12)64947-7.
Chaturvedi S, Malik MY, Rashid M, Singh S, Tiwari V, Gupta P, Shukla S, Singh S, Wahajuddin M. Mechanistic exploration of quercetin against metronidazole induced neurotoxicity in rats: Possible role of nitric oxide isoforms and inflammatory cytokines. Neurotoxicology. July 2020, 79: 1–10. Bibcode:2020NeuTx..79....1C. PMID 32151614. doi:10.1016/j.neuro.2020.03.002.
Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ethanol interaction. The American Journal of Forensic Medicine and Pathology. December 1996, 17 (4): 343–346. PMID 8947362. doi:10.1097/00000433-199612000-00013.
Kudo T, Endo Y, Taguchi R, Yatsu M, Ito K. Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. May 2015, 45 (5): 413–419. PMID 25470432. S2CID 26910995. doi:10.3109/00498254.2014.990948.
Tirkkonen T, Heikkilä P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. Journal of Internal Medicine. October 2010, 268 (4): 359–366. PMID 20698928. S2CID 45449460. doi:10.1111/j.1365-2796.2010.02257.x.
Alauzet C, Aujoulat F, Lozniewski A, Marchandin H. A sequence database analysis of 5-nitroimidazole reductase and related proteins to expand knowledge on enzymes responsible for metronidazole inactivation. Anaerobe. February 2019, 55: 29–34. PMID 30315962. doi:10.1016/j.anaerobe.2018.10.005.已忽略未知参数|orig-date= (帮助)
Leiros HK, Kozielski-Stuhrmann S, Kapp U, Terradot L, Leonard GA, McSweeney SM. Structural basis of 5-nitroimidazole antibiotic resistance: the crystal structure of NimA from Deinococcus radiodurans. The Journal of Biological Chemistry. December 2004, 279 (53): 55840–55849. PMID 15492014. doi:10.1074/jbc.M408044200(英语).
Suárez LJ, Arce RM, Gonçalves C, Furquim CP, Santos NC, Retamal-Valdes B, Feres M. Metronidazole may display anti-inflammatory features in periodontitis treatment: A scoping review. Mol Oral Microbiol. April 2024, 39 (4): 240–259. PMID 38613247. doi:10.1111/omi.12459.
Barr SC, Bowman DD, Heller RL. Efficacy of fenbendazole against giardiasis in dogs. American Journal of Veterinary Research. July 1994, 55 (7): 988–990. PMID 7978640. doi:10.2460/ajvr.1994.55.07.988.
duBouchet L, Spence MR, Rein MF, Danzig MR, McCormack WM. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sexually Transmitted Diseases. March 1997, 24 (3): 156–160. PMID 9132982. S2CID 6617019. doi:10.1097/00007435-199703000-00006.
Rawat A, Singh P, Jyoti A, Kaushik S, Srivastava VK. Averting transmission: A pivotal target to manage amoebiasis. Chemical Biology & Drug Design. August 2020, 96 (2): 731–744. PMID 32356312. S2CID 218475533. doi:10.1111/cbdd.13699.
Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, Poston L. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG. January 2006, 113 (1): 65–74. PMID 16398774. S2CID 11366650. doi:10.1111/j.1471-0528.2005.00788.x.
Iqbal SM, Murthy JG, Banerjee PK, Vishwanathan KA. Metronidazole ototoxicity--report of two cases. The Journal of Laryngology and Otology. April 1999, 113 (4): 355–357. PMID 10474673. S2CID 45989669. doi:10.1017/s0022215100143968.
Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, Vougiouklakis T, Marselos M. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. International Journal of Toxicology. 2007, 26 (5): 423–432. PMID 17963129. S2CID 41230661. doi:10.1080/10915810701583010.
Kudo T, Endo Y, Taguchi R, Yatsu M, Ito K. Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. May 2015, 45 (5): 413–419. PMID 25470432. S2CID 26910995. doi:10.3109/00498254.2014.990948.
Tirkkonen T, Heikkilä P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. Journal of Internal Medicine. October 2010, 268 (4): 359–366. PMID 20698928. S2CID 45449460. doi:10.1111/j.1365-2796.2010.02257.x.
Kraft MY, Kochergin PM, Tsyganova AM, Shlikhunova VS. Synthesis of metronidazole from ethylenediamine. Pharmaceutical Chemistry Journal. 1989, 23 (10): 861–863. S2CID 38187002. doi:10.1007/BF00764821.
Ryan KJ, Ahmad N, Alspaugh JA, Drew WL, Lagunoff M, Pottinger P, Reller LB, Reller ME, Sterling CR, Weissman S. Sherris medical microbiolog Seventh. New York: McGraw Hill LLC. 2018-01-12. ISBN 978-1-259-85981-6. OCLC 1004770160.